Cancer nanotechnology: current status and perspectives

Kemp, Jessica A.; Kwon, Young Jik

doi:10.1186/s40580-021-00282-7

Cited by 133 publications

(77 citation statements)

References 388 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Benefiting from the EPR effect of the nanodrug delivery system, PEG- g -(PBYP- ss -CPT) NPs accumulated in tumors and other organs for a longer period of time. In contrast, cRGD-CPT NPs, in addition to being captured by the liver, 3 accumulated in tumor tissues in higher amounts than PEG- g -(PBYP- ss -CPT) NPs without the targeting molecule. These results suggest that cRGD-CPT NPs have targeting properties and can improve the drug delivery efficiency.…”

Section: Resultsmentioning

confidence: 91%

Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells

Zhou

Zhang

et al. 2022

ACS Omega

View full text Add to dashboard Cite

To overcome the limitation of conventional nanodrugs in tumor targeting efficiency, coupling targeting ligands to polymeric nanoparticles can enhance the specific binding of nanodrugs to tumors. Cyclo(Arg-Gly-Asp- d -Phe-Lys) (abbreviated as c(RGDfK)) peptide has been widely adopted due to its high affinity to the tumor marker α v β 3 integrin receptor. In this study, we develop a cRGD peptide-conjugated camptothecin (CPT) prodrug, which enables self-assembly of nanoparticles for precise targeting and enrichment in tumor tissue. We first synthesized a camptothecin derivative (CPT- ss -N 3 ) with a reduction-sensitive bond and simultaneously modified PEG to obtain cRGD-PEG-N 3 . After ring-opening polymerization of the 2-(but-3-yn-1-yolxy)-2-oxo-1,3,2-dioxaphospholane (BYP), an amphiphilic polymeric prodrug, referred to as cRGD-PEG- g -(PBYP- ss -CPT), was obtained via copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction. The self-assembly in buffer solution of the cRGD-functional prodrug was studied through DLS and TEM. The in vitro drug release behavior of cRGD-PEG- g -(PBYP- ss -CPT) nanoparticles was investigated. The results show that the nanoparticles are reduction-responsive and the bonded CPT can be released. Endocytosis and MTT assays demonstrate that the cRGD-conjugated prodrug has better affinity for tumor cells, accumulates more intracellularly, and is therefore, more effective. The in vivo drug metabolism studies show that nanoparticles greatly prolong the retention time in circulation. By monitoring drug distribution in tumor and in various tissues, we find that free CPT can be rapidly metabolized, resulting in low accumulation in all tissues. However, cRGD-PEG- g -(PBYP- ss -CPT) nanoparticles accumulate in tumor tissues in higher amounts than PEG- g -(PBYP- ss -CPT) nanoparticles, except for the inevitable capture by the liver. This indicates that the nanomedicine with cRGD has a certain targeting property, which can improve drug delivery efficiency.

show abstract

Section: Resultsmentioning

confidence: 91%

Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells

Zhou

Zhang

et al. 2022

ACS Omega

View full text Add to dashboard Cite

show abstract

“…The enhanced targeting capability of DTDSs can favor the reduction of the systemic toxicity of drugs and thereby improve treatment efficacy. 2,3 Among the many available nanoscale drug carriers, liposomes are considered the nanomaterials with the greatest potential in clinical application. A majority of the FDA-approved nanomaterial-drug formulations employ liposomes.…”

Section: Introductionmentioning

confidence: 99%

Optimization of a CE-ICP-MS/MS method for the investigation of liposome–cisplatin nanosystems and their interactions with transferrin

Wróblewska

Samsonowicz-Górski

Kamińska

et al. 2022

J. Anal. At. Spectrom.

View full text Add to dashboard Cite

show abstract

“…Fe-based MOFs (Fe-MOFs) contrast agents are more common than Gd-based and Mn-based MOFs for T 2 -weighted MRI (oral LD50 of Fe is 30 g kg –1 ) [ 48 ]. Gref et al have designed a series of Fe-MOFs (MIL-53, MIL-88A, MIL-89, MIL-100 and MIL-101-NH 2 for MRI and drug delivery, demonstrating excellent therapeutic results [ 49 ].…”

Section: Mof-based Nanotherapeutics For Light-mediated Cancer Diagnosismentioning

confidence: 99%

Application of MOF-based nanotherapeutics in light-mediated cancer diagnosis and therapy

et al. 2022

View full text Add to dashboard Cite

Light-mediated nanotherapeutics have recently emerged as promising strategies to precisely control the activation of therapeutic reagents and imaging probe both in vitro and in vivo, largely ascribed to their unique properties, including minimally invasive capabilities and high spatiotemporal resolution. Nanoscale metal–organic frameworks (NMOFs), a new family of hybrid materials consisting of metal attachment sites and bridging ligands, have been explored as a new platform for enhanced cancer diagnosis and therapy due to their tunable size, modifiable surface, good biocompatibility, high agent loading and, most significantly, their ability to be preferentially deposited in tumors through enhanced permeability and retention (EPR). Especially the light-driven NMOF-based therapeutic platform, which not only allow for increased laser penetration depth and enhanced targeting, but also enable imaging-guided or combined treatments. This review provides up-to-date developments of NMOF-based therapeutic platforms for cancer treatment with emphasis on light-triggered therapeutic strategies and introduces their advances in cancer diagnosis and therapy in recent years. Graphic Abstract

show abstract

Cancer nanotechnology: current status and perspectives

Cited by 133 publications

References 388 publications

Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells

Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells

Optimization of a CE-ICP-MS/MS method for the investigation of liposome–cisplatin nanosystems and their interactions with transferrin

Application of MOF-based nanotherapeutics in light-mediated cancer diagnosis and therapy

Contact Info

Product

Resources

About